What is Brief History of ResMed Company?

ResMed Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

How Did ResMed Revolutionize Respiratory Care?

ResMed, a global leader in respiratory care, has a compelling story of innovation and impact. With a staggering $4.7 billion in revenue for fiscal year 2024 and over 23 million cloud-connected devices, the company's influence is undeniable. But how did this healthcare giant rise to prominence, transforming the treatment of conditions like sleep apnea and COPD?

The ResMed SWOT Analysis reveals the company's strengths and opportunities. Founded in 1989 by Dr. Peter Farrell, ResMed's journey began with the commercialization of the groundbreaking CPAP technology developed by Professor Colin Sullivan. This pivotal moment marked the beginning of ResMed's mission to improve the lives of millions suffering from sleep apnea and other respiratory ailments, establishing its position in the medical devices industry.

The founding of ResMed is directly linked to a pivotal moment in medical history: the invention of Continuous Positive Airway Pressure (CPAP) technology. This technology revolutionized the treatment of obstructive sleep apnea (OSA), a condition that affects millions worldwide. The company's inception was driven by the need to commercialize and improve upon this groundbreaking medical device.

In 1981, Professor Colin Sullivan and his team at the University of Sydney created the first CPAP device. This invention, which initially used a vacuum cleaner pump, marked the beginning of effective, non-invasive treatment for OSA. This innovation laid the groundwork for ResMed's future.

Dr. Peter Farrell established ResMed in June 1989 in Australia, with the specific goal of commercializing Professor Sullivan's CPAP technology. The company's original business model centered on the development and manufacture of equipment for positive airway pressure (PAP) therapy. This marked a significant step in making CPAP technology widely available. The company's name, 'ResMed,' is short for 'Respiratory Medicine,' reflecting its core focus on respiratory health.

Early Days and Innovation

ResMed's early focus was on developing and manufacturing equipment for positive airway pressure (PAP) therapy, specifically CPAP devices. This commitment to innovation has been a core part of their strategy.

• Initial funding for ResMed involved venture capital secured by Dr. Farrell to acquire the core sleep technology rights.
• The company's early products were designed to be more user-friendly and effective than existing solutions.
• ResMed quickly expanded its product line to include masks and other accessories to improve patient comfort and compliance.
• The development of advanced CPAP machines with features like automatic pressure adjustment and data tracking has been a key innovation.

The initial funding for ResMed came from venture capital, which Dr. Farrell secured to obtain the rights to the core sleep technology from the Baxter Centre for Medical Research and the University of Sydney. This strategic move was crucial for the company's launch and early growth. An interesting point is that Professor Sullivan initially sought patent protection for his invention from his university, but this request was declined. He then patented a 'Device for treating snoring sickness' using his own resources.

Key Milestones and Growth

ResMed has achieved several key milestones, including expanding its product line, entering new markets, and making strategic acquisitions. These steps have contributed to its growth and market position.

• 1990s: ResMed expanded its product line and entered international markets.
• 2000s: The company made several strategic acquisitions to broaden its offerings and market reach.
• 2023: ResMed reported revenues of approximately $4.2 billion.
• 2024: ResMed continues to innovate in sleep and respiratory care, with a focus on digital health solutions.

ResMed's journey from a startup to a global leader in respiratory medicine is a testament to its commitment to innovation and patient care. The company's early focus on CPAP technology, combined with strategic investments and product development, has enabled it to achieve significant growth and impact in the healthcare industry. For more details about the company, you can check out Owners & Shareholders of ResMed.

ResMed SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The early growth and expansion of the company, a leader in the medical devices sector, were marked by strategic initiatives to establish a global footprint and diversify its product offerings. This period saw the company transition from its Australian roots to a global entity, driven by innovation and strategic acquisitions. Key milestones, including its Initial Public Offering (IPO) and expansion into digital health, fueled its growth and solidified its position in the market.

Early Global Expansion

Following its founding in Australia in June 1989, the company quickly expanded its operations. An office was opened in San Diego in 1992, which later became its headquarters in 1994 after incorporation in the U.S. This early internationalization set the stage for its global presence. The company's strategic moves were crucial for its expansion in the medical devices market.

Initial Public Offering (IPO)

A significant step in its early growth was the Initial Public Offering (IPO) in 1995. It was dual-listed on NASDAQ (RMD) and the Australian Securities Exchange (ASX: RMD). This IPO provided the necessary capital for global expansion, research, and development. The IPO was a pivotal moment in the company's history.

Expansion in the 2000s

Throughout the 2000s, the company established direct sales operations in key European and Asian markets. It launched successful product lines, such as the S8 series CPAP devices. This expansion broadened its reach and solidified its position in the medical devices industry. This period was marked by strategic market entries and product innovations.

Connected Care and Digital Health

The company's commitment to connected care became evident with the launch of the AirSense platform in 2013. The AirSense 10 series integrated cloud-based patient monitoring via AirView. This focus on software and data analytics positioned the company well against traditional device manufacturers. The company's innovation in sleep therapy continued with its digital health initiatives.

Acquisition of Brightree

In 2016, the company significantly expanded its software-as-a-service (SaaS) solutions by acquiring Brightree for $800 million. This acquisition diversified its revenue streams beyond devices and into post-acute care. This strategic move transformed the company from a product-focused business into a 'health informatics' company, enhancing its mission, vision, and core values.

Recent Financial Performance

As of February 2025, the company's cloud-connected devices support patient health with over 23 million devices globally. The company's revenue for the fiscal year 2024 was approximately $4.7 billion, reflecting a 12% year-over-year growth. For the first half of fiscal year 2025, the company achieved 12% revenue growth, with devices and masks both growing by 11% in constant currency terms, and SaaS organic growth nearing 10%.

ResMed PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The ResMed company has a rich history marked by significant milestones that have shaped its position in the medical device industry. From its inception, ResMed has consistently pushed boundaries, driving innovation in the treatment of sleep apnea and other respiratory conditions. The company's journey reflects a commitment to improving patient care through technological advancements and strategic business decisions, transforming it into a global leader in respiratory care.

ResMed has been at the forefront of innovation in the field of medical devices, particularly in sleep apnea treatment. A notable innovation was the introduction of Expiratory Pressure Relief (EPR), now a standard feature on CPAP machines. The company's commitment to research and development is evident in its extensive patent portfolio, with over 10,000 patent applications.

CPAP Device

ResMed pioneered the commercialization of the CPAP device, a foundational innovation in treating sleep apnea. This device provides continuous positive airway pressure, preventing airway collapse during sleep.

EPR Technology

ResMed introduced Expiratory Pressure Relief (EPR), a feature that makes CPAP therapy more comfortable by reducing pressure during exhalation. This innovation improved patient compliance.

AirSense Platform

The AirSense platform brought connected care to the forefront, integrating cloud-based patient monitoring. This allowed for remote monitoring and improved patient management.

Card-to-Cloud Devices

Due to the chip shortage, ResMed redesigned its AirSense 10 CPAP machines to work around the chip shortage, leading to 'card-to-cloud' devices that required manual data uploads.

Software Solutions

Through acquisitions like Brightree and MEDIFOX DAN, ResMed expanded into SaaS solutions for post-acute care. This diversified its offerings and enhanced its position in the healthcare IT market.

Brand Evolution

In March 2025, ResMed unveiled a comprehensive brand evolution to unify its portfolio and enhance direct consumer engagement. This strategic move aims to streamline its market presence.

Despite its successes, ResMed has faced several challenges. The company experienced supply chain disruptions, particularly a global semiconductor shortage, which affected its ability to meet demand, especially following a major competitor's product recall in June 2021. Additionally, ResMed has navigated competitive pressures and pricing challenges within the healthcare market. To learn more about the ResMed company, you can read Revenue Streams & Business Model of ResMed.

Patent Revocation

In 1993, the Australian Federal Court revoked ResMed's foundational patent for the CPAP machine. This legal challenge impacted the company's early market position.

Supply Chain Disruptions

The global semiconductor shortage caused significant supply chain disruptions, affecting ResMed's ability to meet the demand for its products. This impacted production and sales.

Competitive Pressures

ResMed faces increasing competition and pricing pressures in the healthcare market. This requires continuous innovation and strategic adaptation to maintain market share.

Product Recall

The product recall by a major competitor in June 2021 created an industry-specific imbalance between supply and demand. This presented both challenges and opportunities for ResMed.

Chip Shortage

ResMed had to redesign its AirSense 10 CPAP machines to work around the chip shortage, leading to 'card-to-cloud' devices that required manual data uploads. This impacted operational efficiency.

Market Dynamics

ResMed has to navigate evolving market dynamics, including changing healthcare policies and technological advancements. This requires strategic agility.

ResMed Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The ResMed history is marked by significant milestones, from its inception in Australia to its global expansion and technological advancements in sleep apnea treatment. Founded by Dr. Peter Farrell, the company has consistently innovated in the medical devices sector, particularly in CPAP technology. The company has grown from its humble beginnings to a global leader, treating millions of patients worldwide and consistently pushing the boundaries of respiratory care.

Future Growth

ResMed is strategically positioned to capitalize on the growing demand for sleep apnea and respiratory care solutions. The company's 2030 strategy focuses on accelerating growth and shareholder returns. This includes product innovation, operational excellence, and commercial execution.

Technological Advancements

The company aims to improve the lives of over 500 million people worldwide by 2030. ResMed is leveraging AI and machine learning to enhance therapy performance and user experience. They plan to expand their digital health offerings and invest heavily in R&D.

Financial Outlook

Analyst estimates suggest continued revenue growth, with a forecast of US$5.25 billion in sales for FY25. ResMed also anticipates earnings to grow 20% between FY25 and FY27. The company is expanding its penetration in the U.S. and international markets.

Market Expansion

ResMed is tapping into new growth avenues, particularly in the rapidly growing ventilation market. This includes chronic obstructive pulmonary disease (COPD) and heart-related ventilation and oxygen therapy. The company's future success depends on navigating competition and evolving healthcare policies.

ResMed Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs